Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROL vs MINITRAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NITROL (nitroglycerin) is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase and increases cyclic guanosine monophosphate (c GMP) levels, leading to vasodilation.
Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, which activates guanylyl cyclase, increasing c GMP levels. This leads to dephosphorylation of myosin light chains and vasodilation, particularly in venous capacitance vessels and coronary arteries, reducing preload and afterload.
Treatment of acute angina pectoris,Prophylaxis of angina pectoris (pre-exertional use),Management of acute myocardial infarction (FDA-approved),Congestive heart failure (off-label, in acute settings)
Acute angina pectoris,Prophylaxis of angina pectoris (prior to activities that may provoke an attack),Chronic angina (off-label: long-term prophylaxis),Heart failure associated with acute myocardial infarction (off-label)
Sublingual: 0.3-0.6 mg every 5 minutes as needed for angina, up to 3 doses in 15 minutes. Translingual spray: 1-2 sprays (0.4 mg/spray) under tongue every 5 minutes as needed, max 3 doses in 15 minutes. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours. Intravenous: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes until response, usual range 10-200 mcg/min.
Minitran (nitroglycerin transdermal) is applied as a transdermal patch. Initial dose: 0.2-0.4 mg/hour applied once daily. Titrate based on response and tolerance. Maximum dose: 0.8 mg/hour. The patch is worn for 12-14 hours daily with a 10-12 hour nitrate-free interval to prevent tolerance.
1-4 minutes for nitroglycerin; clinical effect disappears within 30-60 minutes due to rapid metabolism and redistribution.
Terminal half-life is approximately 1-4 minutes for nitroglycerin; clinical effect duration is longer due to tissue distribution.
Primarily metabolized by nitrate reductase in the liver; also undergoes denitration by glutathione-dependent organic nitrate reductase and by hemoglobin in red blood cells.
Rapidly metabolized in the liver by glutathione-organic nitrate reductase, with minor contributions from vascular wall and RBC metabolism. Metabolites include 1,2-glyceryl dinitrate and 1,3-glyceryl dinitrate.
Renal: minimal, <1% unchanged; extensive metabolism by liver, metabolites excreted renally. Biliary/fecal: negligible.
Primarily renal excretion of inactive metabolites; less than 1% excreted unchanged. Biliary/fecal elimination is minimal.
Approximately 60% bound to albumin.
Approximately 60% bound to plasma proteins (albumin).
3.3 L/kg, indicating extensive distribution into tissues.
Vd is about 3 L/kg, indicating extensive tissue distribution.
Sublingual: ~40-60% (first-pass metabolism); Oral: <10% due to high first-pass; Transdermal: ~20-30% with continuous delivery; Intravenous: 100%.
Transdermal: approximately 70-80% of the dose reaches systemic circulation.
No specific adjustment for GFR; monitor for hypotension and methemoglobinemia in severe impairment. Use with caution in dialysis patients.
No specific dose adjustment required for renal impairment. However, patients with severe renal insufficiency (Cr Cl <30 m L/min) may have increased risk of adverse effects; monitor closely.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% and titrate carefully. Child-Pugh C: Avoid use or use with extreme caution, consider alternative therapy.
No specific dose adjustment recommended for Child-Pugh A or B. For Child-Pugh C (severe hepatic impairment), consider reducing dose due to reduced metabolism and increased risk of hypotension; use with caution.
Sublingual/translingual: 5 mcg/kg/dose every 5-10 minutes as needed for acute angina, max 4 doses. IV: Start 0.25-0.5 mcg/kg/min, titrate by 0.5-1 mcg/kg/min, max 5 mcg/kg/min. Not recommended for neonates due to risk of methemoglobinemia.
Safety and effectiveness in pediatric patients have not been established. Use only under expert guidance. Typical initial dose: 0.1-0.2 mg/hour transdermally, titrated cautiously based on clinical response and tolerance.
Start at low end of adult dose (sublingual 0.3 mg, transdermal 0.2 mg/hr, IV 5 mcg/min). Titrate slowly due to increased sensitivity and risk of hypotension. Monitor for orthostatic hypotension.
Elderly patients may be more sensitive to the hypotensive effects. Start at the lower end of dosing range (0.2 mg/hour) and titrate slowly. Monitor blood pressure and heart rate regularly.
Contraindicated in patients with erectile dysfunction who are using phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Do not use MINITRAN in patients taking phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) as this can cause severe hypotension. Additionally, MINITRAN should not be used in patients with early myocardial infarction or severe anemia.
Risk of severe hypotension and syncope, especially in volume-depleted patients or those with low systolic blood pressure; tolerance and cross-tolerance with other nitrates may develop; abrupt cessation may precipitate angina; caution in patients with hypertrophic obstructive cardiomyopathy.
Hypotension; paradoxical bradycardia; tolerance (need for nitrate-free interval); exacerbation of angina with abrupt discontinuation; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Hypersensitivity to nitroglycerin or any component; severe anemia; increased intracranial pressure (e.g., head trauma, cerebral hemorrhage); concurrent use with PDE-5 inhibitors; right ventricular infarction; constrictive pericarditis; cardiac tamponade.
Concurrent use of phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe anemia; increased intracranial pressure (e.g., head trauma, cerebral hemorrhage); acute circulatory failure; hypersensitivity to nitrates.
Alcohol can exacerbate hypotensive effects and should be avoided. No specific food restrictions; however, high-fat meals may delay sublingual absorption but not clinically significant.
Concurrent use of alcohol can cause vasodilation and hypotension. Limit or avoid alcohol. No specific food restrictions.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, nitroglycerin has been shown to be embryotoxic in rats and rabbits at doses 20 times the human dose. Use in first trimester only if clearly needed. During second and third trimesters, may be used for management of preterm labor or pregnancy-induced hypertension, but monitor for maternal hypotension and fetal bradycardia.
Category C. Animal studies show fetal harm; no adequate human studies. Use only if maternal benefit outweighs risk. First trimester: possible teratogenic effects. Second/third trimesters: risk of fetal bradycardia, hypotension, and decreased placental perfusion.
Not known if nitroglycerin is excreted in human milk. M/P ratio not available. Because of potential for serious adverse reactions in nursing infants, discontinue nursing or discontinue drug, taking into account importance of drug to mother. Use with caution if breastfeeding; avoid high doses or continuous exposure.
Likely excreted in breast milk. M/P ratio not established. Use with caution; monitor infant for hypotension.
No specific dose adjustments recommended for pregnancy-related PK changes. However, increased plasma volume and cardiac output in pregnancy may require higher doses for therapeutic effect. Start at lowest effective dose and titrate based on clinical response and blood pressure. For intravenous use in pregnancy, standard non-pregnant doses may be used but with careful titration.
No specific dose adjustments recommended, but use lowest effective dose due to potential for hypotension and decreased placental perfusion.
Nitrol (nitroglycerin) is a potent vasodilator used primarily for angina pectoris. Sublingual tablets should be administered at first sign of attack; patient should be sitting to prevent syncope from hypotension. If pain persists after 3 doses 5 minutes apart, seek emergency care. Tolerance develops with sustained use; avoid long-acting formulations for acute episodes. Monitor for orthostatic hypotension and headache, common side effects. Contraindicated with concurrent use of PDE-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension.
MINITRAN (nitroglycerin transdermal) is used for angina prophylaxis, not acute attacks. Apply to hairless area, rotate sites, and remove for 12-14 hours daily to prevent tolerance. If headache occurs, reduce dose or use acetaminophen. Do not discontinue abruptly to avoid rebound ischemia.
Take sublingual nitroglycerin at the first sign of chest pain; do not swallow. Place tablet under tongue and allow to dissolve.,Sit down before taking to avoid fainting due to drop in blood pressure.,If pain is not relieved after 1 dose, take a second dose after 5 minutes. If not relieved after 3 doses, call 911 immediately.,Store tablets in original glass container, tightly closed, away from light and heat. Replace every 6 months as potency decreases.,Avoid alcohol and erectile dysfunction drugs (e.g., Viagra, Cialis) as they can cause severe hypotension.,Common side effects include headache, dizziness, and flushing. Headache may indicate effectiveness.
Apply patch to clean, dry, hairless skin on chest, arm, or back; rotate sites daily.,Remove patch after 12-14 hours to prevent tolerance; apply new patch at same time next morning.,Do not use for acute angina; use sublingual nitroglycerin instead.,Avoid alcohol and erectile dysfunction drugs like sildenafil; can cause severe hypotension.,Headache may occur; use acetaminophen or reduce dose; do not stop abruptly.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROL vs MINITRAN, answered by our medical review team.
NITROL is a Nitrate Vasodilator that works by NITROL (nitroglycerin) is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase and increases cyclic guanosine monophosphate (c GMP) levels, leading to vasodilation.. MINITRAN is a Nitrate Vasodilator that works by Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, which activates guanylyl cyclase, increasing c GMP levels. This leads to dephosphorylation of myosin light chains and vasodilation, particularly in venous capacitance vessels and coronary arteries, reducing preload and afterload.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROL and MINITRAN depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROL is: Sublingual: 0.3-0.6 mg every 5 minutes as needed for angina, up to 3 doses in 15 minutes. Translingual spray: 1-2 sprays (0.4 mg/spray) under tongue every 5 minutes as needed, max 3 doses in 15 minutes. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours. Intravenous: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes until response, usual range 10-200 mcg/min.. The standard adult dose of MINITRAN is: Minitran (nitroglycerin transdermal) is applied as a transdermal patch. Initial dose: 0.2-0.4 mg/hour applied once daily. Titrate based on response and tolerance. Maximum dose: 0.8 mg/hour. The patch is worn for 12-14 hours daily with a 10-12 hour nitrate-free interval to prevent tolerance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROL and MINITRAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROL is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, nitroglycerin has been shown to be embryotoxic in rats and rabbits at doses 20 times the human d. MINITRAN is classified as Category C. Category C. Animal studies show fetal harm; no adequate human studies. Use only if maternal benefit outweighs risk. First trimester: possible teratogenic effects. Second/third trim. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.